Repligen Corporation (NASDAQ:RGEN – Get Free Report)’s share price was up 6.6% during trading on Wednesday. The company traded as high as $171.56 and last traded at $172.8110. Approximately 165,943 shares traded hands during trading, a decline of 84% from the average daily volume of 1,060,255 shares. The stock had previously closed at $162.18.
Analysts Set New Price Targets
A number of equities research analysts recently commented on RGEN shares. Royal Bank Of Canada upped their target price on Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Barclays raised their price target on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Weiss Ratings cut shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, November 2nd. Canaccord Genuity Group lifted their price objective on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Finally, Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.57.
Check Out Our Latest Report on RGEN
Repligen Trading Up 6.5%
The firm has a market cap of $11.04 billion, a price-to-earnings ratio of -826.03, a PEG ratio of 2.79 and a beta of 1.11. The company has a fifty day moving average price of $176.92 and a 200-day moving average price of $145.71. The company has a current ratio of 9.88, a quick ratio of 8.43 and a debt-to-equity ratio of 0.27.
Repligen (NASDAQ:RGEN – Get Free Report) last posted its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. The firm had revenue of $209.31 million for the quarter, compared to analyst estimates of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. Repligen’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $0.46 earnings per share. As a group, research analysts expect that Repligen Corporation will post 2.07 EPS for the current year.
Institutional Investors Weigh In On Repligen
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Castleark Management LLC purchased a new stake in Repligen during the third quarter worth $10,907,000. Empowered Funds LLC acquired a new position in shares of Repligen in the third quarter worth about $8,982,000. Steward Partners Investment Advisory LLC raised its position in shares of Repligen by 57.1% in the third quarter. Steward Partners Investment Advisory LLC now owns 308 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 112 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Repligen by 17.1% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 56,322 shares of the biotechnology company’s stock worth $10,827,000 after acquiring an additional 8,227 shares in the last quarter. Finally, Wealth Alliance LLC boosted its stake in shares of Repligen by 3.7% during the 3rd quarter. Wealth Alliance LLC now owns 2,636 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 93 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
Repligen Company Profile
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Read More
- Five stocks we like better than Repligen
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
